3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Leukemia, Myeloid, Acute
21
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Myelodysplastic Syndromes
19
Lymphoma, Non-Hodgkin
17
Leukemia, Lymphocytic, Chronic, B-Cell
15
Hodgkin Disease
15
Graft vs Host Disease
13
Lymphoma, Mantle-Cell
12
Leukemia
12
Multiple Myeloma
11
Lymphoma, Large B-Cell, Diffuse
11
Sarcoma
10
Lymphoma
10
Lymphoma, Follicular
9
Lymphoma, B-Cell, Marginal Zone
9
Burkitt Lymphoma
9
Myeloproliferative Disorders
8
Waldenstrom Macroglobulinemia
7
Tuberous Sclerosis
7
Neoplasms
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
7
Hematologic Neoplasms
7
Congenital Abnormalities
7
Primary Myelofibrosis
6
Lymphoma, Large-Cell, Immunoblastic
6
Leukemia, Myelomonocytic, Chronic
6
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Myeloid, Accelerated Phase
6
Breast Neoplasms
6
Osteosarcoma
5
Interventions
apatinib
3
vistusertib
2
olaparib
2
camrelizumab
2
atezolizumab
2
Ipilimumab
2
Everolimus
2
trametinib
1
toripalimab
1
tilsotolimod
1
tazemetostat
1
tazarotene
1
spartalizumab
1
seviteronel
1
sargramostim
1
sacituzumab govitecan
1
rucaparib
1
roniciclib
1
romiplostim
1
pyrotinib
1
phosphorylethanolamine
1
pemigatinib
1
pembrolizumab
1
pazopanib
1
palbociclib
1
niraparib
1
magrolimab
1
lenvatinib
1
irinotecan sucrosofate
1
famitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Solid Tumor
×
Sirolimus
×
Clear all
NCT04469530
2026-02-27
AflacST1903
Emory University
Phase 2
Recruiting
55 enrolled